ES2071666T3 - Derivados de pirazoloisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de pirazoloisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2071666T3
ES2071666T3 ES89312761T ES89312761T ES2071666T3 ES 2071666 T3 ES2071666 T3 ES 2071666T3 ES 89312761 T ES89312761 T ES 89312761T ES 89312761 T ES89312761 T ES 89312761T ES 2071666 T3 ES2071666 T3 ES 2071666T3
Authority
ES
Spain
Prior art keywords
hydrogen
pirazoloisoquinoline
derivatives
procedure
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89312761T
Other languages
English (en)
Inventor
Terrence Michael Hotten
Graham Henry Timms
David Edward Tupper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Industries Ltd
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Application granted granted Critical
Publication of ES2071666T3 publication Critical patent/ES2071666T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPONENTES FARMACEUTICOS DE LA FORMULA EN EL QUE R1 ES HIDROGENO O ALQUIL C1-6, R2 ES HIDROGENO, ALQUIL C1-6 OPCIONALMENTE SUSTITUIDOPORCICLOALQUIL C3-9 O FENIL OPCIONALMENTE SUSTITUIDO, CICLOALQUIL C3-9, FENIL OPCIONALMENTE SUSTITUIDO, O -SR4 DONDE R4 ES ALQUIL C1-6 OPCIONALMENTE SUSTITUIDO POR CICLOALQUIL C3-9 O FENIL OPCIONALMENTE SUSTITUIDO, O CICLOALQUIL C3-9, R3 ES HIDROGENO, ALQUIL C1-6 OPCIONALMENTE SUSTITUIDO POR CICLOALQUIL C3-9 O FENIL OPCIONALMENTE SUSTITUIDO, CICLOALQUIL C3-9, O FENIL SUSTITUIDO OPCIONALMENTE, Y O X E Y SON AMBOS HIDROGENO O JUNTOS SON = O; Y SALES DE ADICCION DE ACIDO DE ELLO. ESOS COMPONENTES MUESTRAN EFECTOS UTILES EN EL SISTEMA NERVIOSO CENTRAL.
ES89312761T 1988-12-08 1989-12-07 Derivados de pirazoloisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2071666T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888828669A GB8828669D0 (en) 1988-12-08 1988-12-08 Organic compounds

Publications (1)

Publication Number Publication Date
ES2071666T3 true ES2071666T3 (es) 1995-07-01

Family

ID=10648173

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89312761T Expired - Lifetime ES2071666T3 (es) 1988-12-08 1989-12-07 Derivados de pirazoloisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (8)

Country Link
US (1) US4963558A (es)
EP (1) EP0375210B1 (es)
JP (1) JPH02202887A (es)
AT (1) ATE122042T1 (es)
CA (1) CA2004826A1 (es)
DE (1) DE68922478T2 (es)
ES (1) ES2071666T3 (es)
GB (1) GB8828669D0 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038077B1 (es) * 1991-10-07 1994-02-01 Univ Alcala Henares Procedimiento de obtencion de antibioticos y citostaticos pirazoloisoquinolinicos.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
AU2005222421B2 (en) 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
MX2013002186A (es) 2010-08-27 2013-06-28 Corcept Therapeutics Inc Moduladores de azadecalina de piridil-amina fusionada.
CN103298343A (zh) 2011-01-07 2013-09-11 科赛普特治疗公司 类固醇和糖皮质激素受体拮抗剂组合疗法
US20130225633A1 (en) * 2012-02-27 2013-08-29 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
PT3338781T (pt) * 2012-05-25 2019-11-29 Corcept Therapeutics Inc Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetonas
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP4219494B1 (en) * 2013-11-25 2026-03-25 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
SG11201908790PA (en) 2017-03-31 2019-10-30 Corcept Therapeutics Inc Glucocorticoid receptor modulators to treat cervical cancer
AU2019404026B2 (en) 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3131263C (en) 2019-02-22 2024-01-02 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US11903945B2 (en) 2019-12-11 2024-02-20 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
KR20230017829A (ko) 2020-05-27 2023-02-06 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c8과 cyp3a4의 이중 기질인 파클리탁셀의 병용 투여
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12616698B2 (en) 2021-05-05 2026-05-05 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1132553A (en) * 1978-10-13 1982-09-28 Gary L. Olson Isoquinoline derivatives
US4230861A (en) * 1979-01-22 1980-10-28 Eli Lilly And Company 1-And/or 7-substituted-6-hydroxy (or oxo)-3-decahydroquinoline carboxylic acids
US4468401A (en) * 1982-11-03 1984-08-28 Eli Lilly And Company Method of blocking peripheral norepinephrine release
IL72729A (en) * 1983-09-26 1988-02-29 Lilly Co Eli Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them
US4596871A (en) * 1983-09-26 1986-06-24 Eli Lilly And Company Pyrazole-ring alkylated pyrazoloquinolines
US4762843A (en) * 1986-09-15 1988-08-09 Warner-Lambert Company Hetero [f] fused carbocyclic pyridines as dopaminergic agents

Also Published As

Publication number Publication date
CA2004826A1 (en) 1990-06-08
GB8828669D0 (en) 1989-01-11
ATE122042T1 (de) 1995-05-15
JPH02202887A (ja) 1990-08-10
DE68922478T2 (de) 1997-02-06
US4963558A (en) 1990-10-16
DE68922478D1 (de) 1995-06-08
EP0375210A1 (en) 1990-06-27
EP0375210B1 (en) 1995-05-03

Similar Documents

Publication Publication Date Title
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
ES2100302T3 (es) Procedimiento para la fabricacion de composiciones de poliuretano cationico y sales de amonio cuaternario.
ES2058292T3 (es) Derivados de indol.
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
MX9206474A (es) Derivados de n-fenilalanil y n-fenilgliclil del dipeptido del acido l-azetidina 2-carboxilico y aldheido de l-arginina, proceso para su preparacion y composicion farmaceutica que los contiene
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
ES2083773T3 (es) Derivados de 1,3-dihidro-2h-imidazo(4,5-b)quinolin-2-ona como inhibidores de fosfodiesterasa.
ES2059408T3 (es) Un proceso para la preparacion de un compuesto.
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
DK0687253T3 (da) Hidtil ukendte 4-aminopyridiner, fremgangsmåde til deres fremstilling samt lægemidler indeholdende disse forbindelser
ES2062395T3 (es) Nuevos compuestos de bencimidazol y su uso.
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES512842A0 (es) "procedimiento de preparar derivados carboxamidicos".
ES2059335T3 (es) Derivados de pirido(3,2,1-ij)-1,3,4-benzoxadiazina, procedimiento para su obtencion, preparados farmaceuticos correspondientes y productos intermedios utilizables en el procedimiento.
MX9206939A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaceutica que los comprende
MX9201356A (es) Derivados de piperidina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9303124A (es) Compuestos organicos de benzodiazepina, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen.
ES2113664T3 (es) Derivados de aminoacidos como inhibidores de la no sintasa.
ES2104841T3 (es) Fosfono-aminoacidos bencimidazolicos.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
ES2090024T3 (es) Compuestos de cefemo y procedimientos para su preparacion.
ES2102043T3 (es) Derivados de 22-en-25-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que los contienen, asi como su utilizacion en calidad de medicamentos.
AR002025A1 (es) Derivados de 4-(1h-indol-1-il)-1-piperidinilo, su uso y un procedimiento para su preparacion, una composicion farmaceutica que los contiene, unprocedimiento para la preparacion de dicha composicion farmaceutica.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 375210

Country of ref document: ES